Market data shows that users of GLP-1 weight loss drugs in the US are driving higher sales of premium chocolate, contrary to earlier expectations of declining demand. Households using these medications account for a larger share of chocolate purchases despite reduced overall appetite. This trend highlights a shift toward quality over quantity in indulgences.
Recent analysis from market researcher Circana indicates that about 15% of US households use GLP-1 weight loss drugs, yet these same households make up 17.5% of total chocolate sales. Swiss chocolatier Lindt & Spruengli reported a nearly 17% increase in premium chocolate sales among users in 2025, compared to just 6.5% growth among non-users. This development challenges predictions from analysts who anticipated a significant drop in food industry volumes by 2027 due to the appetite-suppressing effects of these medications.
The shift appears tied to changes in consumer behavior. With GLP-1 drugs reducing hunger and promoting satiety, users tend to consume smaller amounts but opt for higher-quality treats when they do indulge. Premium brands like Lindt are benefiting from this preference for satisfaction over volume, even as total caloric intake decreases.
Looking ahead, the rollout of oral versions of GLP-1 drugs is expected to broaden the user base, including more men and younger patients. For clinicians, this underscores the importance of tailored dietary advice, as the medications curb overall appetite but do not fully eliminate cravings for palatable foods like sweets. Data suggests users still incorporate moderate amounts of premium confectionery into their routines, requiring guidance to maintain balanced nutrition in weight management.
Market experts note that while some sectors of the food industry may face pressures, premium categories seem resilient amid evolving preferences.
